{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T03:06:43Z","timestamp":1784084803392,"version":"3.55.0"},"reference-count":20,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Diabetes and its Complications"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.jdiacomp.2026.109361","type":"journal-article","created":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T01:04:04Z","timestamp":1781312644000},"page":"109361","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["From obesity guideline to diabetes practice: WHO GLP-1 recommendations between promise, uncertainty and global inequity"],"prefix":"10.1016","volume":"40","author":[{"given":"Michail","family":"Nomikos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manfredi","family":"Rizzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulkarim","family":"AlMakadma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jdiacomp.2026.109361_bb0005","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1001\/jama.2025.24288","article-title":"World Health Organization guideline on the use and indications of glucagon-like peptide-1 therapies for the treatment of obesity in adults","volume":"335","author":"Celletti","year":"2026","journal-title":"JAMA"},{"key":"10.1016\/j.jdiacomp.2026.109361_bb0010","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1093\/nutrit\/nux014","article-title":"Lifestyle recommendations for the prevention and management of metabolic syndrome: an international panel recommendation","volume":"75","author":"P\u00e9rez-Mart\u00ednez","year":"2017","journal-title":"Nutr Rev"},{"key":"10.1016\/j.jdiacomp.2026.109361_bb0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.jdiacomp.2025.109045","article-title":"Obesity and its management in primary care setting","volume":"39","author":"Ibrahim","year":"2025","journal-title":"J Diabetes Complications"},{"key":"10.1016\/j.jdiacomp.2026.109361_bb0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2026.156494","article-title":"Emerging incretin- and multi-agonist-based treatments - the continued refinement and continuous expansion of a potent therapeutic armamentarium for cardio-kidney-liver-metabolic diseases and beyond","volume":"177","author":"Muzurovi\u0107","year":"2026","journal-title":"Metabolism"},{"key":"10.1016\/j.jdiacomp.2026.109361_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2023.155710","article-title":"Safety and efficacy of the new, oral, small-molecule, GLP-1 receptor agonists orforglipron and danuglipron for the treatment of type 2 diabetes and obesity: systematic review and meta-analysis of randomized controlled trials","volume":"149","author":"Karakasis","year":"2023","journal-title":"Metabolism"},{"key":"10.1016\/j.jdiacomp.2026.109361_bb0030","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/S0140-6736(25)02105-1","article-title":"Glucagon-like receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits","volume":"407","author":"Nauck","year":"2026","journal-title":"Lancet"},{"key":"10.1016\/j.jdiacomp.2026.109361_bb0035","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s13300-020-00962-3","article-title":"Liraglutide reduces carotid intima-media thickness by reducing small dense low-density lipoproteins in a real-world setting of patients with type 2 diabetes: a novel anti-atherogenic effect","volume":"12","author":"Nikolic","year":"2021","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.jdiacomp.2026.109361_bb0040","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.2147\/DMSO.S351982","article-title":"The emerging role of dual GLP-1 and GIP receptor agonists in glycemic management and cardiovascular risk reduction","author":"Rizvi","year":"2022","journal-title":"Diabetes Metab Syndr Obes"},{"key":"10.1016\/j.jdiacomp.2026.109361_bb0045","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1111\/dom.15410","article-title":"Effect of tirzepatide on albuminuria levels and renal function in patients with type 2 diabetes mellitus: a systematic review and multilevel meta-analysis","volume":"26","author":"Karakasis","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jdiacomp.2026.109361_bb0050","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2025-085304","article-title":"Weight regain after cessation of medication for weight management: systematic review and meta-analysis","volume":"392","author":"West","year":"2026","journal-title":"BMJ"},{"key":"10.1016\/j.jdiacomp.2026.109361_bb0055","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1111\/dom.14725","article-title":"Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension","volume":"24","author":"Wilding","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jdiacomp.2026.109361_bb0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2025.177885","article-title":"The effects of GLP-1 receptor agonists on body composition in patients with type 2 diabetes, overweight or obesity: a meta-analysis of randomized controlled trials","volume":"1003","author":"Lu","year":"2025","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.jdiacomp.2026.109361_bb0065","article-title":"Pharmacological privilege: how glucagon-like peptide-1 (GLP-1) medications are widening health inequalities","volume":"17","author":"Brennan-Davies","year":"2025","journal-title":"Cureus"},{"key":"10.1016\/j.jdiacomp.2026.109361_bb0070","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s13300-025-01838-0","article-title":"Modern management of CKM syndrome: use of GLP-1 receptor agonists in a multidisciplinary setting-expert group recommendations from Kuwait","volume":"17","author":"Aldahi","year":"2026","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.jdiacomp.2026.109361_bb0075","doi-asserted-by":"crossref","DOI":"10.1007\/s13300-026-01868-2","article-title":"Persistence-dependent effectiveness of tirzepatide on the cardio-metabolic-kidney syndrome outcomes in obesity: real-world evidence from the United Arab Emirates","author":"Rangraze","year":"2026","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.jdiacomp.2026.109361_bb0080","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1007\/s13300-024-01615-5","article-title":"Modern management of cardiometabolic continuum: from overweight\/obesity to prediabetes\/type 2 diabetes mellitus. Recommendations from the Eastern and Southern Europe Diabetes and Obesity Expert Group","volume":"15","author":"Janez","year":"2024","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.jdiacomp.2026.109361_bb0085","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/S0140-6736(18)32822-8","article-title":"The global syndemic of obesity, undernutrition, and climate change: the lancet commission report","volume":"393","author":"Swinburn","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jdiacomp.2026.109361_bb0090","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/s41591-020-0803-x","article-title":"Joint international consensus statement for ending stigma of obesity","volume":"26","author":"Rubino","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.jdiacomp.2026.109361_bb0095","first-page":"884","article-title":"Non-alcoholic fatty liver disease, metabolic syndrome, and type 2 diabetes mellitus: where do we stand today?","volume":"19","author":"Mitrovic","year":"2022","journal-title":"Arch Med Sci"},{"key":"10.1016\/j.jdiacomp.2026.109361_bb0100","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines13020368","article-title":"Obesity: recent advances and future perspectives","volume":"13","author":"Jani\u0107","year":"2025","journal-title":"Biomedicines"}],"container-title":["Journal of Diabetes and its Complications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056872726001066?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056872726001066?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T03:01:29Z","timestamp":1784084489000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1056872726001066"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":20,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S1056872726001066"],"URL":"https:\/\/doi.org\/10.1016\/j.jdiacomp.2026.109361","relation":{},"ISSN":["1056-8727"],"issn-type":[{"value":"1056-8727","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"From obesity guideline to diabetes practice: WHO GLP-1 recommendations between promise, uncertainty and global inequity","name":"articletitle","label":"Article Title"},{"value":"Journal of Diabetes and its Complications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdiacomp.2026.109361","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109361"}}